217 related articles for article (PubMed ID: 37870965)
1. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Kamran SC; Zhou Y; Otani K; Drumm M; Otani Y; Wu S; Wu CL; Feldman AS; Wszolek M; Lee RJ; Saylor PJ; Lennerz J; Van Allen E; Willers H; Hong TS; Liu Y; Davicioni E; Gibb EA; Shipley WU; Mouw KW; Efstathiou JA; Miyamoto DT
Clin Cancer Res; 2023 Dec; 29(24):5116-5127. PubMed ID: 37870965
[TBL] [Abstract][Full Text] [Related]
2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
3. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
Gil-Jimenez A; van Dorp J; Contreras-Sanz A; van der Vos K; Vis DJ; Braaf L; Broeks A; Kerkhoven R; van Kessel KEM; Ribal MJ; Alcaraz A; Wessels LFA; Seiler R; Wright JL; Mengual L; Boormans J; van Rhijn BWG; Black PC; van der Heijden MS
Eur Urol; 2023 Apr; 83(4):313-317. PubMed ID: 35965206
[TBL] [Abstract][Full Text] [Related]
5. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
6. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
Arcangeli G; Strigari L; Arcangeli S
Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
[TBL] [Abstract][Full Text] [Related]
7.
Li Q; Damish AW; Frazier Z; Liu D; Reznichenko E; Kamburov A; Bell A; Zhao H; Jordan EJ; Gao SP; Ma J; Abbosh PH; Bellmunt J; Plimack ER; Lazaro JB; Solit DB; Bajorin D; Rosenberg JE; D'Andrea AD; Riaz N; Van Allen EM; Iyer G; Mouw KW
Clin Cancer Res; 2019 Feb; 25(3):977-988. PubMed ID: 29980530
[TBL] [Abstract][Full Text] [Related]
8. Genomic characterization of response to chemoradiation in urothelial bladder cancer.
Desai NB; Scott SN; Zabor EC; Cha EK; Hreiki J; Sfakianos JP; Ramirez R; Bagrodia A; Rosenberg JE; Bajorin DF; Berger MF; Bochner BH; Zelefsky MJ; Kollmeier MA; Ostrovnaya I; Al-Ahmadie HA; Solit DB; Iyer G
Cancer; 2016 Dec; 122(23):3715-3723. PubMed ID: 27479538
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.
Koga F; Numao N; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
Urol Oncol; 2013 Oct; 31(7):1270-5. PubMed ID: 22386622
[TBL] [Abstract][Full Text] [Related]
10. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
11. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
Tanabe K; Yoshida S; Koga F; Inoue M; Kobayashi S; Ishioka J; Tamura T; Sugawara E; Saito K; Akashi T; Fujii Y; Kihara K
Clin Genitourin Cancer; 2015 Aug; 13(4):e243-e251. PubMed ID: 25936588
[TBL] [Abstract][Full Text] [Related]
12. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
Mak KS; Smith AB; Eidelman A; Clayman R; Niemierko A; Cheng JS; Matthews J; Drumm MR; Nielsen ME; Feldman AS; Lee RJ; Zietman AL; Chen RC; Shipley WU; Milowsky MI; Efstathiou JA
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1028-1036. PubMed ID: 27727064
[TBL] [Abstract][Full Text] [Related]
13. Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.
Jiang DM; Chung P; Kulkarni GS; Sridhar SS
Curr Oncol Rep; 2020 Feb; 22(2):14. PubMed ID: 32008105
[TBL] [Abstract][Full Text] [Related]
14. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
[TBL] [Abstract][Full Text] [Related]
15. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
16. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
[TBL] [Abstract][Full Text] [Related]
18. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Van Allen EM; Mouw KW; Kim P; Iyer G; Wagle N; Al-Ahmadie H; Zhu C; Ostrovnaya I; Kryukov GV; O'Connor KW; Sfakianos J; Garcia-Grossman I; Kim J; Guancial EA; Bambury R; Bahl S; Gupta N; Farlow D; Qu A; Signoretti S; Barletta JA; Reuter V; Boehm J; Lawrence M; Getz G; Kantoff P; Bochner BH; Choueiri TK; Bajorin DF; Solit DB; Gabriel S; D'Andrea A; Garraway LA; Rosenberg JE
Cancer Discov; 2014 Oct; 4(10):1140-53. PubMed ID: 25096233
[TBL] [Abstract][Full Text] [Related]
19. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD; Daneshmand S; Izadmehr S; Gonzalez-Kozlova E; Chan KG; Lewis S; Achkar BE; Dorff TB; Cetnar JP; Neil BO; D'Souza A; Mamtani R; Kyriakopoulos C; Jun T; Gogerly-Moragoda M; Brody R; Xie H; Nie K; Kelly G; Horowitz A; Kinoshita Y; Ellis E; Nose Y; Ioannou G; Cabal R; Del Valle DM; Haines GK; Wang L; Mouw KW; Samstein RM; Mehrazin R; Bhardwaj N; Yu M; Zhao Q; Kim-Schulze S; Sebra R; Zhu J; Gnjatic S; Sfakianos J; Pal SK
Nat Med; 2023 Nov; 29(11):2825-2834. PubMed ID: 37783966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
